mTOR inhibitors: Facing new challenges ahead

Current Medicinal Chemistry

Volumn 18, Issue 18, 2011, Pages 2743-2762

  Mavrommati, I ^a   Maffucci, T ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Akt; Cancer; mTOR; PI3K; Rapalogs; Rapamycin

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 (6 AMINO 9 PURINYLMETHYL) 5 METHYL 3 (2 METHYLPHENYL) 3H QUINAZOLIN 4 ONE; 2 MORPHOLINO 8 PHENYLCHROMONE; CISPLATIN; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; FIGITUMUMAB; GEMCITABINE; INITIATION FACTOR 4E; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHARMACOLOGICAL BIOMARKER; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PP 242; PROTEIN KINASE B; RAPAMYCIN; RIDAFOROLIMUS; S6 KINASE; SELUMETINIB; SORAFENIB; TEMOZOLOMIDE; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 765;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG STABILITY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; KIDNEY CARCINOMA; NEGATIVE FEEDBACK; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PROTEIN FUNCTION; SARCOMA; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL MEDICINE; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 79959351376     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711796011247     Document Type: Article

References (175)

1. Heitman, J., Movva, N. R.; Hall, M. N. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science, 1991, 253(5022), 905-909. (Pubitemid 21917235)
2. Brown, E. J.; Albers, M. W.; Shin, T. B.; Ichikawa, K.; Keith, C. T.; Lane, W. S.; Schreiber, S. L. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature, 1994, 369(6483), 756-758.
3. Sabatini, D. M.; Erdjument-Bromage, H.; Lui, M.; Tempst, P.; Snyder, S. H. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycindependent fashion and is homologous to yeast TORs. Cell, 1994, 78(1), 35-43. (Pubitemid 24228298)
4. Sabers, C. J.; Martin, M. M.; Brunn, G. J.; Williams, J. M.; Dumont, F. J.; Wiederrecht, G.; Abraham, R. T. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J. Biol. Chem., 1995, 270(2), 815-822.
5. Sengupta, S.; Peterson, T. R.; Sabatini, D. M. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol. Cell, 2010, 40(2), 310-322.
6. Wullschleger, S.; Loewith, R.; Hall, M. N. TOR signaling in growth and metabolism. Cell, 2006, 124(3), 471-484. (Pubitemid 43199434)
7. Guertin, D. A.; Sabatini, D. M. Defining the role of mTOR in cancer. Cancer Cell, 2007, 12(1), 9-22. (Pubitemid 47001784)
8. Menon, S., Manning, B. D. Common corruption of the mTOR signaling network in human tumors. Oncogene, 2008, 27 Suppl 2, S43-S51.
9. Zoncu, R.; Efeyan, A.; Sabatini, D. M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell. Biol., 2011, 12(1), 21-35.
10. Scott, P. H.; Brunn, G. J.; Kohn, A. D.; Roth, R. A.; Lawrence, J. C. Jr. Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway. Proc Natl Acad Sci U S A., 1998, 95(13), 7772-7777. (Pubitemid 28293329)
11. Inoki, K.; Li, Y.; Zhu, T.; Wu, J.; Guan, K. L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol., 2002, 4(9), 648-657. (Pubitemid 34993700)
12. Hara, K.; Yonezawa, K.; Weng, Q. P.; Kozlowski, M. T.; Belham C.; Avruch, J. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism, J. Biol. Chem., 1998, 274(2), 14484-14494. (Pubitemid 28319170)
13. Wang, X.; Campbell, L. E.; Miller, C. M.; Proud, C. G. Amino acid availability regulates p70 S6 kinase and multiple translation factors. Biochem J., 1998, 334(Pt 1), 261-267. (Pubitemid 28420997)
14. Inoki, K.; Zhu, T.; Guan, K. L. TSC2 mediates cellular energy response to control cell growth and survival, Cell, 2003, 115(5), 577-590. (Pubitemid 37506046)
15. Corradetti, M. N.; Inoki, K.; Bardeesy, N.; DePinho, R. A.; Guan, K. L. Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev., 2004, 18(13), 1533-1538. (Pubitemid 38868905)
16. Wang, X.; Proud, C. G. mTORC1 signaling: what we still don't know. J. Mol. Cell Biol., 2010, Dec. 7. [Epub ahead of print]
17. Reiling, J. H.; Sabatini, D. M. Stress and mTORture signaling. Oncogene, 2006, 25(48), 6373-6383. (Pubitemid 44582282)
18. Bai, X.; Jiang, Y. Key factors in mTOR regulation. Cell Mol Life Sci., 2010, 67(2), 239-253.
19. Manning, B. D.; Tee, A. R.; Logsdon, M. N.; Blenis, J.; Cantley, L. C. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell., 2002, 10(1), 151-162. (Pubitemid 34876569)
20. Inoki, K.; Li, Y.; Xu, T.; Guan, K. L. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev., 2003, 17(15), 1829-1834. (Pubitemid 36944560)
21. Saucedo, L. J.; Gao, X.; Chiarelli, D. A.; Li, L.; Pan, D.; Edgar, B. A. Rheb promotes cell growth as a component of the insulin/TOR signalling network. Nat. Cell Biol., 2003, 5(6), 566-571. (Pubitemid 36781092)
22. Zhang, Y.; Gao, X.; Saucedo, L. J.; Ru, B.; Edgar, B. A.; Pan, D. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat. Cell Biol., 2003, 5(6), 578-581. (Pubitemid 36781094)
23. Roux, P. P.; Ballif, B. A.; Anjum, R.; Gygi, S. P.; Blenis, J. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci U S A., 2004, 101(37), 13489-13494. (Pubitemid 39238430)
24. Tee, A. R.; Anjum, R.; Blenis, J. Inactivation of the tuberous sclerosis complex-1 and-2 gene products occurs by phosphoinositide 3-kinase/Aktdependent and-independent phosphorylation of tuberin. J. Biol. Chem., 2003, 278(39), 37288-37296. (Pubitemid 37175245)
25. Tee, A. R.; Fingar, D. C.; Manning, B. D.; Kwiatkowski, D. J.; Cantley, L. C.; Blenis, J. Tuberous sclerosis complex-1 and-2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A, 2002, 99(21), 13571-13576. (Pubitemid 35215423)
26. Sancak, Y., Peterson, T. R., Shaul, Y. D., Lindquist, R. A., Thoreen, C. C., Bar-Peled, L., Sabatini, D. M. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science, 2008, 320(5882), 1496-1501. (Pubitemid 351929429)
27. Zinzalla, V.; Stracka, D.; Oppliger, W.; Hall, M. N. Activation of mTORC2 by Association with the Ribosome. Cell, 2011, 144(5), 757-768.
28. Gan, X.; Wang, J.; Su, B.; Wu, D. Evidence for direct activation of mTORC2 kinase activity by phosphatidylinositol 3, 4, 5-trisphosphate. J. Biol. Chem., 2011, Feb. 10. [Epub ahead of print]
29. Brown, E. J.; Beal, P. A.; Keith, C. T.; Chen, J.; Shin, T. B.; Schreiber, S. L. Control of p70 S6 kinase by kinase activity of FRAP in vivo. Nature, 1995, 377(6548), 441-446.
30. Gingras, A. C.; Kennedy, S. G.; O'Leary, M. A.; Sonenberg, N.; Hay, N. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt (PKB) signaling pathway. Genes Dev., 1998, 12(4), 502-513. (Pubitemid 28101013)
31. Burnett, P. E.; Barrow, R. K.; Cohen, N. A.; Snyder, S. H.; Sabatini, D. M. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci U S A, 1998, 95(4), 1432-1437. (Pubitemid 28103409)
32. Rosner, M.; Fuchs, C.; Siegel, N.; Valli, A.; Hengstschläger, M. Functional interaction of mammalian target of rapamycin complexes in regulating mammalian cell size and cell cycle. Hum. Mol. Genet., 2009, 18(17), 3298-3310.
33. Jacinto, E.; Loewith, R.; Schmidt, A.; Lin, S.; Rüegg, M. A.; Hall, A.; Hall, M. N. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol., 2004, 6(11), 1122-1128. (Pubitemid 39468014)
34. Sarbassov, D. D.; Ali, S. M.; Kim, D. H.; Guertin, D. A.; Latek, R. R.; Erdjument-Bromage, H.; Tempst, P.; Sabatini, D. M. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol., 2004, 14(14), 1296-1302. (Pubitemid 38991819)
35. Sarbassov, D. D.; Ali, S. M.; Sengupta, S.; Sheen, J. H.; Hsu, P. P.; Bagley, A. F.; Markhard, A. L.; Sabatini, D. M. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell., 2006, 22(2), 159-168.
36. Huang, J.; Wu, S.; Wu, C.-L.; Manning, B. D. Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors. Cancer Res., 2009, 69(15), 6107-6114.
37. Tato, I.; Bartrons, R.; Ventura, F.; Rosa, J. L. Amino acids activate mTOR complex 2 via PI3K/Akt signalling. J. Biol. Chem., 2011, 286(8), 6128-6124.
38. Efeyan, A.; Sabatini, D. M. mTOR and cancer: many loops in one pathway. Curr Opin Cell Biol., 2010, 22(2), 169-176.
39. Wang, X.; Sun, S.-Y. Enhancing mTOR-targeted cancer therapy. Expert Opin Ther Targets, 2009, 13(10), 1193-1203.
40. Falasca, M. PI3K/Akt signalling pathway specific inhibitors: a novel strategy to sensitize cancer cells to anti-cancer drugs. Curr. Pharm. Des., 2010, 16(12), 1410-1416.
41. Wong, K. K.; Engelman, J. A.; Cantley, L. C. Targeting the PI3K signaling pathway in cancer. Curr. Opin. Genet. Dev., 2010, 20(1), 87-90.
42. Engelman, J. A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer, 2009, 9(8), 550-562.
43. van Veelen, W.; Korsse, S. E.; van de Laar, L.; Peppelenbosch, M. P. The long and winding road to rational treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling. Oncogene, 2011 Jan 24. [Epub ahead of print]
44. Vézina, C.; Kudelski, A.; Sehgal, S. N. Rapamycin (AY-22, 989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J. Antibiot. (Tokyo), 1975, 28(10), 721-726.
45. Martel, R. R.; Klicius, J.; Galet, S. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can. J. Physiol. Pharmacol., 1977, 55(1), 48-51. (Pubitemid 8061941)
46. Baker, H., Sidorowicz, A., Sehgal, S. N., Vézina, C. Rapamycin (AY-22, 989), a new antifungal antibiotic. III. In vitro and in vivo evaluation. J. Antibiot. (Tokyo), 1978, 31(6), 539-545. (Pubitemid 8402848)
47. Gibbons, J. J.; Abraham, R. T.; Yu, K. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin Oncol, 2009, 36 Suppl 3, S3-S17.
48. Hidalgo, M.; Rowinsky, E. K. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene, 2000, 19(56), 6680-6686. (Pubitemid 32197708)
49. Douros, J.; Suffness, M. New antitumor substances of natural origin. Cancer Treat Rev., 1981, 8(1), 63-87. (Pubitemid 11088289)
50. Tsang, C. K.; Qi, H.; Liu, L. F.; Zheng, X. F. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov Today, 2007, 12(3-4), 112-124. (Pubitemid 46176669)
51. Eng, C. P., Sehgal, S. N., Vézina, C. Activity of rapamycin (AY-22, 989) against transplanted tumors. J. Antibiot. (Tokyo), 1984, 37(10), 1231-1237. (Pubitemid 14015835)
52. Houghton, P. J. Everolimus. Clin. Cancer Res., 2010, 16(5), 1368-1372.
53. Dancey, J. mTOR signaling and drug development in cancer. Nat. Rev. Clin. Oncol., 2010, 7(4), 209-219.
54. Dancey, J. E.; Curiel, R.; Purvis, J. Evaluating Temsirolimus activity in multiple tumours: a review of clinical trials. Semin Oncol, 2009, 36 Suppl 3, S46-S58.
55. Yap, T. A.; Garrett, M. D.; Walton, M. I.; Raynaud, F.; de Bono, J. S.; Workman, P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr. Opin. Pharmacol., 2008, 8(4), 393-412.
56. Choi, J.; Chen, J.; Schreiber, S. L.; Clardy, J. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science, 1996, 273(5272), 239-242. (Pubitemid 26285890)
57. Kim, D. H.; Sarbassov, D. D.; Ali, S. M.; King, J. E.; Latek, R. R.; Erdjument-Bromage, H.; Tempst, P.; Sabatini, D. M. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell, 2002, 110(2), 163-175. (Pubitemid 34876545)
58. Oshiro, N.; Yoshino, K.; Hidayat, S.; Tokunaga, C.; Hara, K.; Eguchi, S.; Avruch, J.; Yonezawa, Y. Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function. Genes Cell, 2004, 9(4), 359-366. (Pubitemid 38514871)
59. Schalm, S. S.; Tee, A. R.; Blenis, J. Characterization of a conserved C-terminal motif (RSPRR) in ribosomal protein S6 kinase 1 required for its mammalian target of rapamycin-dependent regulation. J. Biol. Chem., 2005, 280(12), 11101-11106. (Pubitemid 40418414)
60. Nojima, H.; Tokunaga, C.; Eguchi, S.; Oshiro, N.; Hidayat, S.; Yoshino, K.; Hara, K.; Tanaka, N.; Avruch, J.; Yonezawa, K. The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J. Biol. Chem., 2003, 278(18), 15461-15464. (Pubitemid 36799651)
61. Choo, A. Y.; Blenis, J. Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy. Cell Cycle, 2009, 8(4), 567-572.
62. Yip, C. K.; Murata, K.; Walz, T.; Sabatini, D. M.; Kang, S. A. Structure of the human mTOR complex I and its implications for rapamycin inhibition. Mol Cell., 2010, 38(5), 768-774.
63. Shor, B.; Zhang, W. G.; Toral-Barza, L.; Lucas, J.; Abraham, R. T.; Gibbons, J. J.; Yu, K. A new pharmacological action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis. Cancer Res., 2008, 68(8), 2934-2943. (Pubitemid 351556294)
64. Le Tourneau, C.; Faivre, S.; Serova, M.; Raymond, E. mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work? Br. J. Cancer, 2008, 99(8), 1197-1203.
65. Huang, S.; Bjornsti, M. A.; Houghton, P. J. Rapamycins: mechanism of action and cellular resistance. Cancer Biol. Ther., 2003, 2(3), 222-232.
66. Kurmasheva R. T., Huang S., Houghton P. J. Predicted mechanisms of resistance to mTOR inhibitors. Br. J. Cancer., 2006, 95(8), 955-960. (Pubitemid 44606818)
67. Haruta, T.; Uno, T.; Kawahara, J.; Takano, A.; Egawa, K.; Sharma, P. M.; Olefsky, J. M.; Kobayashi, M. A rapamycin-sensitive pathway downregulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol. Endocrinol., 2000, 14(6), 783-794. (Pubitemid 32260492)
68. Tremblay, F.; Marette, A. Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells. J. Biol. Chem., 2001, 276(41), 38052-38060.
69. Shi, Y.; Yan, H.; Frost, P.; Gera, J.; Lichtenstein, A. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by upregulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol. Cancer Ther., 2005, 4(10), 1533-1540. (Pubitemid 41556435)
70. O'Reilly, K. E.; Rojo, F.; She, Q.-B.; Solit, D.; Mills, G. B.; Smith, D.; Lane, H.; Hofmann, F.; Hicklinn, D. J.; Ludwig, D. L.; Baselga, J.; Rosen, N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res., 2006, 66(3), 1500-1508. (Pubitemid 43259931)
71. Tamburini, J.; Chapuis, N.; Bardet, V.; Park, S.; Sujobert, P.; Willems, L.; Ifrah, N.; Dreyfus, F.; Mayeux, P.; Lacombe, C.; Bouscary, D. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood, 2008, 111(1), 379-382.
72. Zeng, Z.; Sarbassov dos, D.; Samudio, I. J.; Yee, K. W.; Munsell, M. F.; Ellen Jackson, C.; Giles, F. J.; Sabatini, D. M.; Andreeff, M.; Konopleva, M. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood, 2007, 109(8), 3509-3512. (Pubitemid 46572543)
73. Wan, X.; Harkavy, B.; Shen, N.; Grohar, P.; Helman, L. J. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene, 2007, 26(13), 1932-1940. (Pubitemid 46474636)
74. Liu, J.; Stevens, P. D.; Gao, T. mTOR-dependent regulation of PHLPP expression controls the rapamycin sensitivity in cancer cells. J. Biol. Chem., 2011, 286(8), 6510-6520.
75. Brognard, J.; Newton, A. C. PHLiPPing the switch on Akt and protein kinase C signaling. Trends Endocrinol Metab., 2008, 19(6), 223-230. (Pubitemid 351993013)
76. Huang, J.; Manning, B. D. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem. Soc. Trans., 2009, 37(Pt 1), 217-222.
77. Sancak, Y.; Thoreen, C. C.; Peterson, T. R.; Lindquist, R. A.; Kang, S. A.; Spooner, E.; Carr, S. A.; Sabatini, D. M. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol. Cell., 2007, 25(6), 903-915. (Pubitemid 46436534)
78. Vander Haar, E.; Lee, S. I.; Bandhakavi, S.; Griffin, T. J.; Kim, D. H. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat. Cell Biol., 2007, 9(3), 316-323. (Pubitemid 46344611)
79. Sarbassov, D. D.; Guertin, D. A.; Ali, S. M.; Sabatini, D. M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science, 2005, 307(5712), 1098-1101. (Pubitemid 40262113)
80. Huang, J.; Dibble, C. C.; Matsuzaki, M.; Manning, B. D. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol. Cell Biol., 2008, 28(12), 4104-4115. (Pubitemid 351812994)
81. Oh, W. J.; Wu, C. C.; Kim, S. J.; Facchinetti, V.; Julien, L. A.; Finlan, M.; Roux, P. P.; Su, B.; Jacinto, E. mTORC2 can associate with ribosomes to promote cotranslational phosphorylation and stability of nascent Akt polypeptide. EMBO J., 2010, 29(23), 3939-3951.
82. Wu, Y. T.; Ouyang, W.; Lazorchak, A. S.; Liu, D.; Shen, H. M.; Su, B. mTOR Complex 2 Targets Akt for Proteasomal Degradation via Phosphorylation at the Hydrophobic Motif. J. Biol. Chem., 2011, Feb. 14. [Epub ahead of print]
83. Carracedo, A.; Ma, L.; Teruya-Feldstein, J.; Rojo, F.; Salmena, L.; Alimonti, A.; Egia, A.; Sasaki, A. T.; Thomas, G.; Kozma, S. C.; Papa, A.; Nardella, C.; Cantley, L. C.; Baselga, J.; Pandolfi, P. P. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Inv., 2008, 118(9), 3065-3074.
84. Wang, X.; Hawk, N.; Yue, P.; Kauh, J.; Ramalingam, S. S.; Fu, H.; Khuri, F. R.; Sun, S. Y. Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy. Cancer Biol Ther., 2008, 7(12), 1952-1958.
85. Chaturvedi, D.; Gao, X.; Cohen, M. S.; Taunton, J.; Patel, T. B. Rapamycin induces transactivation of the EGFR and increases cell survival. Oncogene, 2009, 28(9), 1187-1196.
86. Zhang, H.; Bajraszewski, N.; Wu, E.; Wang, H.; Moseman, A. P.; Dabora, S. L.; Griffin, J. D.; Kwiatkowski, D. J. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J. Clin. Invest., 2007, 117(3), 730-738. (Pubitemid 46348531)
87. Sun, S. Y.; Rosenberg, L. M.; Wang, X.; Zhou, Z.; Yue, P.; Fu, H.; Khuri, F. R. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res., 2005, 65(16), 7052-7058. (Pubitemid 41161231)
88. Wang, X.; Yue, P.; Chan, C. B.; Ye, K.; Ueda, T.; Watanabe-Fukunaga, R.; Fukunaga, R.; Fu, H.; Khuri, F. R.; Sun, S. Y. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase dependent and Mnkmediated eIF4E phosphorylation. Mol. Cell Biol., 2007, 27(21), 7405-7413. (Pubitemid 350033648)
89. Hsieh, A. C.; Ruggero, D. Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer. Clin. Cancer Res., 2010, 16(20), 4914-4920.
90. Choo, A. Y.; Yoon, S. O.; Kim, S. G.; Roux, P. P.; Blenis, J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci U S A., 2008, 105(45), 17414-17419.
91. Hsieh, A. C.; Costa, M.; Zollo, O.; Davis, C.; Feldman, M. E.; Testa, J. R.; Meyuhas, O.; Shokat, K. M.; Ruggero D. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell, 2010, 17(3), 249-261.
92. Santiskulvong, C.; Konecny, G. E.; Fekete, M.; Chen, K. Y.; Karam, A.; Mulholland, D. J.; Eng, C.; Wu, H.; Song, M.; Dorigo, O. Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma. Clin. Cancer Res., 2011 Mar. 3. [Epub ahead of print]
93. Wang, X.; Yue, P.; Kim, Y. A.; Fu, H.; Khuri, F. R.; Sun, S. Y. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Res., 2008, 68(18), 7409-7418.
94. Couderc, C.; Poncet, G.; Villaume, K.; Blanc, M.; Gadot, N.; Walter, T.; Lepinasse, F.; Hervieu, V.; Cordier-Bussat, M.; Scoazec, J. Y.; Roche, C. Targeting the PI3K/mTOR Pathway in Murine Endocrine Cell Lines In vitro and in vivo Effects on Tumor Cell Growth. Am. J. Pathol., 2011, 178(1), 336-344.
95. Fan, Q. W.; Knight, Z. A.; Goldenberg, D. D.; Yu, W.; Mostov, K. E.; Stokoe, D.; Shokat, K. M.; Weiss, W. A. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell, 2006, 9(5), 341-349. (Pubitemid 43668732)
96. Workman, P.; Clarke, P. A.; Raynaud, F. I.; van Montfort, R. L. Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res., 2010, 70(6), 2146-2157.
97. Bender, A.; Opel, D.; Naumann, I.; Kappler, R.; Friedman, L.; von Schweinitz, D.; Debatin, K. M.; Fulda, S. PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards proapoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis. Oncogene, 2011, 30(4), 494-503.
98. Werzowa, J.; Koehrer, S.; Strommer, S.; Cejka, D.; Fuereder, T.; Zebedin, E.; Wacheck, V. Vertical Inhibition of the mTORC1/mTORC2/PI3K Pathway Shows Synergistic Effects against Melanoma In vitro and In vivo. J. Invest. Dermatol., 2011, 131(2), 495-503.
99. Raynaud, F. I.; Eccles, S.; Clarke, P. A.; Hayes, A.; Nutley, B.; Alix, S.; Henley, A.; Di-Stefano, F.; Ahmad, Z.; Guillard, S.; Bjerke, L. M.; Kelland, L.; Valenti, M.; Patterson, L.; Gowan, S.; de Haven Brandon, A.; Hayakawa, M.; Kaizawa, H.; Koizumi, T.; Ohishi, T.; Patel, S.; Saghir, N.; Parker, P.; Waterfield, M.; Workman, P. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res., 2007, 67(12), 5840-5850. (Pubitemid 46985018)
100. Folkes, A. J.; Ahmadi, K.; Alderton, W. K.; Alix, S.; Baker, S. J.; Box, G.; Chuckowree, I. S.; Clarke, P. A.; Depledge, P.; Eccles, S. A.; Friedman, L. S.; Hayes, A.; Hancox, T. C.; Kugendradas, A.; Lensun, L.; Moore, P.; Olivero, A. G.; Pang, J.; Patel, S.; Pergl-Wilson, G. H.; Raynaud, F. I.; Robson, A.; Saghir, N.; Salphati, L.; Sohal, S.; Ultsch, M. H.; Valenti, M.; Wallweber, H. J.; Wan, N. C.; Wiesmann, C.; Workman, P.; Zhyvoloup, A.; Zvelebil, M. J.; Shuttleworth, S. J. The identification of 2-(1H-indazol-4-yl)-6-(4- methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3, 2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J. Med. Chem., 2008, 51(18), 5522-5532.
101. Maira, S. M.; Stauffer, F.; Brueggen, J.; Furet, P.; Schnell, C.; Fritsch, C.; Brachmann, S.; Chène, P.; De Pover, A.; Schoemaker, K.; Fabbro, D.; Gabriel, D.; Simonen, M.; Murphy, L.; Finan, P.; Sellers, W.; García-Echeverría, C. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther., 2008, 7(7), 1851-1863.
102. Serra, V., Markman, B., Scaltriti, M., Eichhorn, P. J., Valero, V., Guzman, M., Botero, M. L., Llonch, E., Atzori, F., Di Cosimo, S., Maira, M., Garcia-Echeverria, C., Parra, J. L., Arribas, J., Baselga, J. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res., 2008, 68(19), 8022-8030.
103. Cho, D. C.; Cohen, M. B.; Panka, D. J.; Collins, M.; Ghebremichael, M.; Atkins, M. B.; Signoretti, S.; Mier, J. W. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin. Cancer Res., 2010, 16(14), 3628-3638.
104. Cao, P.; Maira, S. M.; García-Echeverría, C.; Hedley, D. W. Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts. Br. J. Cancer, 2009, 100(8), 1267-1276.
105. Liu, T. J.; Koul, D.; LaFortune, T.; Tiao, N.; Shen, R. J.; Maira, S. M.; Garcia-Echevrria, C.; Yung, W. K. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol. Cancer Ther., 2009, 8(8), 2204-2210.
106. McMillin, D. W.; Ooi, M.; Delmore, J.; Negri, J.; Hayden, P.; Mitsiades, N.; Jakubikova, J.; Maira, S. M.; Garcia-Echeverria, C.; Schlossman, R.; Munshi, N. C.; Richardson, P. G.; Anderson, K. C.; Mitsiades, C. S. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res., 2009, 69(14), 5835-5842.
107. Chapuis, N.; Tamburini, J.; Green, A. S.; Vignon, C.; Bardet, V.; Neyret, A.; Pannetier, M.; Willems, L.; Park, S.; Macone, A.; Maira, S. M.; Ifrah, N.; Dreyfus, F.; Herault, O.; Lacombe, C.; Mayeux, P.; Bouscary, D. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin. Cancer Res., 2010, 16(22), 5424-5435.
108. Schnell, C. R.; Stauffer, F.; Allegrini, P. R.; O'Reilly, T.; McSheehy, P. M.; Dartois, C.; Stumm, M.; Cozens, R.; Littlewood-Evans, A.; García-Echeverría, C.; Maira, S. M. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res., 2008, 68(16), 6598-6607.
109. Molckovsky, A.; Siu, L. L. First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting. J. Hematol. Oncol., 2008, 20, 1.
110. Venkatesan, A. M.; Chen, Z.; dos Santos, O.; Dehnhardt, C.; Santos, E. D.; Ayral-Kaloustian, S.; Mallon, R.; Hollander, I.; Feldberg, L.; Lucas, J.; Yu, K.; Chaudhary, I.; Mansour, T. S. PKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor. Bioorg Med Chem Lett., 2010, 20(19), 5869-5873.
111. Venkatesan, A. M.; Dehnhardt, C. M.; Delos Santos, E.; Chen, Z.; Dos Santos, O.; Ayral-Kaloustian, S.; Khafizova, G.; Brooijmans, N.; Mallon, R.; Hollander, I.; Feldberg, L.; Lucas, J.; Yu, K.; Gibbons, J.; Abraham, R. T.; Chaudhary, I.; Mansour, T. S. Bis (morpholino-1, 3, 5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/ mammalian target of rapamycin inhibitors: discovery of compound 26(PKI-587), a highly efficacious dual inhibitor. J. Med. Chem., 2010, 53(6), 2636-2645.
112. Legrier, M. E.; Yang, C. P.; Yan, H. G.; Lopez-Barcons, L.; Keller, S. M.; Pérez-Soler, R.; Horwitz, S. B.; McDaid, H. M. Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression. Cancer Res., 2007, 67(23), 11300-11308. (Pubitemid 350248556)
113. Kinkade, C. W.; Castillo-Martin, M.; Puzio-Kuter, A.; Yan, J.; Foster, T. H.; Gao, H.; Sun, Y.; Ouyang, X.; Gerald, W. L.; Cordon-Cardo, C.; Abate-Shen, C. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormonerefractory prostate cancer in a preclinical mouse model. J. Clin. Invest., 2008, 118(9), 3051-3064.
114. Chang, Q.; Chapman, M. S.; Miner, J. N.; Hedley, D. W. Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts. BMC Cancer, 2010, 10, 515.
115. Chang, Q.; Chen, E.; Hedley, D. W. Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models. Cancer Biol Ther., 2009, 8(20), 1893-1901.
116. Konicek, B. W.; Stephens, J. R.; McNulty, A. M.; Robichaud, N.; Peery, R. B.; Dumstorf, C. A.; Dowless, M. S.; Iversen, P.; Parsons, S. H.; Ellis, K. E.; McCann, D. J.; Pelletier, J.; Furic, L.; Yingling, J. M.; Stancato, L. F.; Sonenberg, N.; Graff, J. R. Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases. Cancer Res., 2011, 71(5), 1849-1857.
117. Quek, R. H.; Wang, Q.; Morgan, J. A.; Shapiro, G. I.; Butrynski, J. E.; Ramaiya, N.; Huftalen, T.; Jederlinic, N.; Manola, J.; Wagner, A. J.; Demetri, G. D.; George S. Combination mTOR and IGF-1R inhibition: Phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin. Cancer Res., 2011, 17(4), 871-879.
118. Flaig, T. W.; Costa, L. J.; Gustafson, D. L.; Breaker, K.; Schultz, M. K.; Crighton, F.; Kim, F. J.; Drabkin, H. Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib. Br. J. Cancer, 2010, 103(6), 796-801.
119. Schmid, K.; Bago-Horvath, Z.; Berger, W.; Haitel, A.; Cejka, D.; Werzowa, J.; Filipits, M.; Herberger, B.; Hayden, H.; Sieghart, W. Dual inhibition of EGFR and mTOR pathways in small cell lung cancer. Br. J. Cancer, 2010, 103(5), 622-628.
120. Abraham, R. T.; Gibbons, J. J. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin. Cancer Res., 2007, 13(11), 3109-3114. (Pubitemid 46944891)
121. Feldman, M. E.; Apsel, B.; Uotila, A.; Loewith, R.; Knight, Z. A.; Ruggero, D.; Shokat, K. M. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol., 2009, 7(2), e38.
122. Thoreen, C. C.; Kang, S. A.; Chang, J. W.; Liu, Q.; Zhang, J.; Gao, Y.; Reichling, L. J.; Sim, T.; Sabatini, D. M.; Gray, N. S. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem., 2009, 284(12), 8023-8032.
123. García-Martínez, J. M.; Moran, J.; Clarke, R. G.; Gray, A.; Cosulich, S. C.; Chresta, C. M.; Alessi, D. R. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J., 2009, 421(1), 29-42.
124. Yu, K.; Toral-Barza, L.; Shi, C.; Zhang, W.-G.; Lucas, J.; Shor, B.; Kim, J.; Verheijen, J.; Curran, K.; Malwitz, D. J.; Cole, D. C.; Ellingboe, J.; Ayral-Kaloustian, S.; Mansour, T. S.; Gibbons, J. J.; Abraham, R. T.; Nowak, P.; Zask, A. Biochemical, cellular and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res., 2009, 69(15), 6232-6240
125. Apsel, B.; Blair, J. A.; Gonzalez, B.; Nazif, T. M.; Feldman, M. E.; Aizenstein, B.; Hoffman, R.; Williams, R. L.; Shokat, K. M.; Knight, Z. A. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat. Chem. Biol., 2008, 4(11), 691-699.
126. Janes, M. R.; Limon, J. J.; So, L.; Chen, J.; Lim, R. J.; Chavez, M. A.; Vu, C.; Lilly, M. B.; Mallya, S.; Ong, S. T.; Konopleva, M.; Martin, M. B.; Ren, P.; Liu, Y.; Rommel, C.; Fruman, D. A. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat. Med., 2010, 16(2), 205-213.
127. Hoang, B.; Frost, P.; Shi, Y.; Belanger, E.; Benavides, A.; Pezeshkpour, G.; Cappia, S.; Guglielmelli, T.; Gera, J.; Lichtenstein, A. Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. Blood, 2010, 116(22), 4560-4568.
128. Liu, Q.; Chang, J. W.; Wang, J.; Kang, S. A.; Thoreen, C. C.; Markhard, A.; Hur, W.; Zhang, J.; Sim, T.; Sabatini, D. M.; Gray, N. S. Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl) phenyl)-9-(quinolin-3-yl) benzo[h][1, 6]naphthyridin-2 (1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. J. Med. Chem., 2010, 53(19), 7), 7146-7155.
129. Dowling, R. J. O.; Topisirovic, I.; Fonseca, B. D.; Sonenberg, N. Dissecting the role of mTOR: Lessons from mTOR inhibitors. Bioch Biophys Acta, 2010, 1804(3), 433-439.
130. Zask, A.; Verheijen, J. C.; Curran, K.; Kaplan, J.; Richard, D. J.; Nowak, P.; Malwitz, D. J.; Brooijmans, N.; Bard, J.; Svenson, K.; Lucas, J.; Toral-Barza, L.; Zhang, W. G.; Hollander, I.; Gibbons, J. J.; Abraham, R. T.; Ayral-Kaloustian, S.; Mansour, T. S.; Yu, K. ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines. J. Med. Chem., 2009, 52(16), 5013-5016.
131. Yu, K.; Shi, C.; Toral-Barza, L.; Lucas, J.; Shor, B.; Kim, J. E.; Zhang, W. G.; Mahoney, R.; Gaydos, C.; Tardio, L.; Kim, S. K.; Conant, R.; Curran, K.; Kaplan, J.; Verheijen, J.; Ayral-Kaloustian, S.; Mansour, T. S.; Abraham, R. T.; Zask, A.; Gibbons, J. J. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res., 2010, 70(2), 621-631.
132. Chresta, C. M.; Davies, B. R.; Hickson, I.; Harding, T.; Cosulich, S.; Critchlow, S. E.; Vincent, J. P.; Ellston, R.; Jones, D.; Sini, P.; James, D.; Howard, Z.; Dudley, P.; Hughes, G.; Smith, L.; Maguire, S.; Hummersone, M.; Malagu, K.; Menear, K.; Jenkins, R.; Jacobsen, M.; Smith, G. C.; Guichard, S.; Pass, M. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo
133. García-Martínez, J. M.; Wullschleger, S.; Preston, G.; Guichard, S.; Fleming, S.; Alessi, D. R.; Duce, S. L. Effect of PI3K-and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice. Br. J. Cancer, 2011, Mar. 15. [Epub ahead of print]
134. Falasca, M.; Chiozzotto, D.; Godage, H. Y.; Mazzoletti, M.; Riley, A. M.; Previdi, S.; Potter, B. V.; Broggini, M.; Maffucci, T. A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1, 3, 4, 5, 6-pentakisphosphate. Br. J. Cancer, 2010, 102(1), 104-114.
135. Zask, A.; Kaplan, J.; Verheijen, J. C.; Richard, D. J.; Curran, K.; Brooijmans, N.; Bennett, E. M.; Toral-Barza, L.; Hollander, I.; Ayral-Kaloustian, S.; Yu, K. Morpholine derivatives greatly enhance the selectivity of mammalian target of rapamycin (mTOR) inhibitors. J. Med. Chem., 2009, 52(24), 7942-7945.
136. Menear, K. A.; Gomez, S.; Malagu, K.; Bailey, C.; Blackburn, K.; Cockcroft, X. L.; Ewen, S.; Fundo, A.; Le Gall, A.; Hermann, G.; Sebastian, L.; Sunose, M.; Presnot, T.; Torode, E.; Hickson, I.; Martin, N. M.; Smith, G. C.; Pike, K. G. Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTOR. Bioorg. Med. Chem. Lett., 2009, 19(20), 5898-5901.
137. Malagu, K.; Duggan, H.; Menear, K.; Hummersone, M.; Gomez, S.; Bailey, C.; Edwards, P.; Drzewiecki, J.; Leroux, F.; Quesada, M. J.; Hermann, G.; Maine, S.; Molyneaux, C. A.; Le Gall, A.; Pullen, J.; Hickson, I.; Smith, L.; Maguire, S.; Martin, N.; Smith, G.; Pass, M. The discovery and optimisation of pyrido[2, 3-d]pyrimidine-2, 4-diamines as potent and selective inhibitors of mTOR kinase. Bioorg. Med. Chem. Lett., 2009, 19(20), 5950-5953.
138. Liu, Q.; Wang, J.; Kang, S. A.; Thoreen, C. C.; Hur, W.; Ahmed, T.; Sabatini, D. M.; Gray, N. S. Discovery of 9-(6-Aminopyridin-3-yl)-1-(3- (trifluoromethyl) phenyl) benzo[h][1, 6]naphthyridin-2 (1H)-one (Torin2) as a Potent, Selective, and Orally Available Mammalian Target of Rapamycin (mTOR) Inhibitor for Treatment of Cancer. J. Med. Chem., 2011, 54(5), 1), 1473-1480.
139. Richard, D. J.; Verheijen, J. C.; Curran, K.; Kaplan, J.; Toral-Barza, L.; Hollander, I.; Lucas, J.; Yu, K.; Zask A. Incorporation of water-solubilizing groups in pyrazolopyrimidine mTOR inhibitors: discovery of highly potent and selective analogs with improved human microsomal stability. Bioorg. Med. Chem. Lett, 2009, 19(24), 6830-6835.
140. Urano, J.; Sato, T.; Matsuo, T.; Otsubo, Y.; Yamamoto, M.; Tamanoi, F. Point mutations in TOR confer Rheb-independent growth in fission yeast and nutrient-independent mammalian TOR signaling in mammalian cells. Proc. Natl. Acad. Sci. U S A, 2007, 104(9), 3514-3519. (Pubitemid 46364190)
141. Ohne, Y.; Takahara, T.; Hatakeyama, R.; Matsuzaki, T.; Noda, M.; Mizushima, N.; Maeda, T. Isolation of hyperactive mutants of mammalian target of rapamycin. J. Biol. Chem., 2008, 283(46), 31861-31870.
142. Sturgill, T. W.; Hall, M. N. Activating mutations in TOR are in similar structures as oncogenic mutations in PI3KCalpha. ACS Chem Biol., 2009, 4(12), 999-1015.
143. Sato, T.; Nakashima, A.; Guo, L.; Coffman, K.; Tamanoi, F. Single aminoacid changes that confer constitutive activation of mTOR are discovered in human cancer. Oncogene, 2010, 29(18), 2746-2752.
144. Hardt, M.; Chantaravisoot, N.; Tamanoi, F. Activating mutations of TOR (target of rapamycin). Genes Cells., 2011, 16(2), 141-151.
145. Robbins, C. M.; Tembe, W. A.; Baker, A.; Sinari, S.; Moses, T. Y.; Beckstrom-Sternberg, S.; Beckstrom-Sternberg, J.; Barrett, M.; Long, J.; Chinnaiyan, A.; Lowey, J.; Suh, E.; Pearson, J. V.; Craig, D. W.; Agus, D. B.; Pienta, K. J.; Carpten, J. D. Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Res., 2011, 21(1), 47-55.
146. Sparks, C. A.; Guertin, D. A. Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene, 2010, 29(26), 3733-3744.
147. Foster, K. G.; Fingar, D. C. Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J. Biol. Chem., 2010, 285(19), 14071-14077.
148. Tao, Z.; Barker, J.; Shi, S. D.; Gehring, M.; Sun, S. Steady-state kinetic and inhibition studies of the mammalian target of rapamycin (mTOR) kinase domain and mTOR complexes. Biochemistry, 2010, 49(39), 8488-8498.
149. Cheng, S. W.; Fryer, L. G.; Carling, D.; Shepherd, P. R. Thr2446 is a novel mammalian target of rapamycin (mTOR) phosphorylation site regulated by nutrient status. J. Biol. Chem., 2004, 279(16), 15719-15722. (Pubitemid 38509255)
150. Acosta-Jaquez, H. A.; Keller, J. A.; Foster, K. G.; Ekim, B.; Soliman, G. A.; Feener, E. P.; Ballif, B. A.; Fingar, D. C. Site-specific mTOR phosphorylation promotes mTORC1-mediated signaling and cell growth. Mol. Cell Biol., 2009, 29(15), 4308-4324.
151. Sekulic, A., Hudson, C. C., Homme, J. L., Yin, P., Otterness, D. M., Karnitz, L. M., Abraham, R. T. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res., 2000, 60(13), 3504-3513. (Pubitemid 30482170)
152. Holz, M. K.; Blenis, J. Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. J. Biol. Chem., 2005, 280(28), 26089-26093. (Pubitemid 41022201)
153. Chiang, G. G.; Abraham, R. T. Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J. Biol. Chem., 2005, 280(27), 25485-25490. (Pubitemid 40962253)
154. Hirashima, K.; Baba, Y.; Watanabe, M.; Karashima, R.; Sato, N.; Imamura, Y.; Hiyoshi, Y.; Nagai, Y.; Hayashi, N.; Iyama, K.; Baba, H. Phosphorylated mTOR expression is associated with poor prognosis for patients with esophageal squamous cell carcinoma. Ann. Surg. Oncol, 2010, 17(9), 2486-2493.
155. Kruck, S., Bedke, J., Hennenlotter, J., Ohneseit, P. A., Kuehs, U., Senger, E., Sievert, K. D., Stenzl, A. Activation of mTOR in renal cell carcinoma is due to increased phosphorylation rather than protein overexpression. Oncol Rep., 2010, 23(1), 159-163.
156. Shida, T.; Kishimoto, T.; Furuya, M.; Nikaido, T.; Koda, K.; Takano, S.; Kimura, F.; Shimizu, H.; Yoshidome, H.; Ohtsuka, M.; Tanizawa, T.; Nakatani, Y.; Miyazaki, M. Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors. Cancer Chemother Pharmacol, 2010, 65(5), 889-893.
157. Peterson, R. T.; Beal, P. A.; Comb, M. J.; Schreiber, S. L. FKBP12-rapamycinassociated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions. J. Biol. Chem., 2000, 275(10), 7416-7423. (Pubitemid 30146297)
158. Copp, J.; Manning, G.; Hunter, T. TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Res., 2009, 69(5), 1821-1827.
159. Soliman, G. A.; Acosta-Jaquez, H. A.; Dunlop, E. A.; Ekim, B.; Maj, N. E.; Tee, A. R.; Fingar, D. C. mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action. J. Biol. Chem., 2010, 285(11), 7866-7879.
160. Carrière, A.; Cargnello, M.; Julien, L. A.; Gao, H.; Bonneil, E.; Thibault, P.; Roux, P. P. Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation. Curr. Biol., 2008, 18(17), 1269-1277.
161. Carriere, A.; Romeo, Y.; Acosta-Jaquez, H. A.; Moreau, J.; Bonneil, E.; Thibault, P.; Fingar, D. C.; Roux, P. P. ERK1/2 phosphorylate Raptor to promote Ras-dependent activation of mTOR complex 1(mTORC1). J. Biol. Chem., 2011, 286(1), 567-577.
162. Foster, K. G.; Acosta-Jaquez, H. A.; Romeo, Y.; Ekim, B.; Soliman, G. A.; Carriere, A.; Roux, P. P.; Ballif, B. A.; Fingar, D. C. Regulation of mTOR complex 1(mTORC1) by raptor S863 and multisite phosphorylation. J. Biol. Chem., 2010, 285(1), 80-94.
163. Wang, L.; Lawrence, J. C. Jr; Sturgill, T. W.; Harris, T. E. Mammalian target of rapamycin complex 1(mTORC1) activity is associated with phosphorylation of raptor by mTOR. J. Biol. Chem., 2009, 284(22), 14693-14697.
164. Gwinn, D. M.; Shackelford, D. B.; Egan, D. F.; Mihaylova, M. M.; Mery, A.; Vasquez, D. S.; Turk, B. E.; Shaw, R. J. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell., 2008, 30(2), 214-226. (Pubitemid 351626684)
165. Ramírez-Valle, F.; Badura, M. L.; Braunstein, S.; Narasimhan, M.; Schneider, R. J. Mitotic raptor promotes mTORC1 activity, G (2)/M cell cycle progression, and internal ribosome entry site-mediated mRNA translation. Mol. Cell Biol., 2010, 30(13), 3151-3164.
166. Gwinn, D. M.; Asara, J. M.; Shaw, R. J. Raptor is phosphorylated by cdc2 during mitosis. PLoS One, 2010, 5(2), e9197.
167. Dibble, C. C.; Asara, J. M.; Manning, B. D. Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol. Cell Biol., 2009, 29(21), 5657-5670.
168. Julien, L. A.; Carriere, A.; Moreau, J.; Roux, P. P. mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Mol Cell Biol., 2010, 30(4), 908-921.
169. Treins, C.; Warne, P. H.; Magnuson, M. A.; Pende, M.; Downward, J. Rictor is a novel target of p70 S6 kinase-1. Oncogene, 2010, 29(7), 1003-1016.
170. Gao, D.; Wan, L.; Inuzuka, H.; Berg, A. H.; Tseng, A.; Zhai, B.; Shaik, S.; Bennett, E.; Tron, A. E.; Gasser, J. A.; Lau, A.; Gygi, S. P.; Harper, J. W.; DeCaprio, J. A.; Toker, A.; Wei, W. Rictor forms a complex with Cullin-1 to promote SGK1 ubiquitination and destruction. Mol. Cell, 2010, 39(5), 797-808.
171. Peterson, T. R.; Laplante, M.; Thoreen, C. C.; Sancak, Y.; Kang, S. A.; Kuehl, W. M.; Gray, N. S.; Sabatini, D. M. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell, 2009, 137(5), 873-886.
172. Kovacina, K. S.; Park, G. Y.; Bae, S. S.; Guzzetta, A. W.; Schaefer, E.; Birnbaum, M. J.; Roth, R. A. Identification of a proline-rich Akt substrate as a 14-3-3 binding partner. J. Biol. Chem., 2003, 278(12), 10189-10194. (Pubitemid 36800278)
173. Oshiro, N.; Takahashi, R.; Yoshino, K.-I.; Tanimura, K.; Nakashima, A.; Eguchi, S.; Miyamoto, T.; Hara, K.; Takehana, K.; Avruch, J.; Kikkawa, U.; Yonezawa K. The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. J. Biol. Chem., 2007, 282(28), 20329-20339. (Pubitemid 47100038)
174. Fonseca, B. D.; Smith, E. M.; Lee, V. H.; MacKintosh, C.; Proud, C. G. PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex. J. Biol. Chem., 2007, 282(34), 24514-24524. (Pubitemid 47347551)
175. Madhunapantula, S. V.; Sharma, A.; Robertson, G. P. PRAS40 deregulates apoptosis in malignant melanoma. Cancer Res., 2007, 67(8), 3626-3636. (Pubitemid 46762147)